Get Premium to unlock powerful stock data
PTC Therapeutics Inc logo

PTC Therapeutics Inc

$ 30.35 -0.27 (-0.88%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 2.17B
Enterprise V:
$ 2.11B
Volume:
639.99K
Avg Vol (2M):
607.76K
Also Trade In:
Volume:
639.99K
Market Cap $:
2.17B
PE Ratio:
At Loss
Avg Vol (2-Month):
607.76K
Enterprise Value $:
2.11B
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for PTC Therapeutics Inc () from 2013 to May 29 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. PTC Therapeutics stock (PTCT) PE ratio as of May 29 2022 is 0. More Details

PTC Therapeutics PE Ratio (TTM) Chart

EMBED

PTC Therapeutics PE Ratio (TTM) Historical Data

Total 1248
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
PTC Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-05-29At Loss 2022-03-28At Loss
2022-05-27At Loss 2022-03-25At Loss
2022-05-26At Loss 2022-03-24At Loss
2022-05-25At Loss 2022-03-23At Loss
2022-05-24At Loss 2022-03-22At Loss
2022-05-23At Loss 2022-03-21At Loss
2022-05-20At Loss 2022-03-18At Loss
2022-05-19At Loss 2022-03-17At Loss
2022-05-18At Loss 2022-03-16At Loss
2022-05-17At Loss 2022-03-15At Loss
2022-05-16At Loss 2022-03-14At Loss
2022-05-13At Loss 2022-03-11At Loss
2022-05-12At Loss 2022-03-10At Loss
2022-05-11At Loss 2022-03-09At Loss
2022-05-10At Loss 2022-03-08At Loss
2022-05-09At Loss 2022-03-07At Loss
2022-05-06At Loss 2022-03-04At Loss
2022-05-05At Loss 2022-03-03At Loss
2022-05-04At Loss 2022-03-02At Loss
2022-05-03At Loss 2022-03-01At Loss
2022-05-02At Loss 2022-02-28At Loss
2022-04-29At Loss 2022-02-25At Loss
2022-04-28At Loss 2022-02-24At Loss
2022-04-27At Loss 2022-02-23At Loss
2022-04-26At Loss 2022-02-22At Loss
2022-04-25At Loss 2022-02-21At Loss
2022-04-22At Loss 2022-02-18At Loss
2022-04-21At Loss 2022-02-17At Loss
2022-04-20At Loss 2022-02-16At Loss
2022-04-19At Loss 2022-02-15At Loss
2022-04-18At Loss 2022-02-14At Loss
2022-04-15At Loss 2022-02-11At Loss
2022-04-14At Loss 2022-02-10At Loss
2022-04-13At Loss 2022-02-09At Loss
2022-04-12At Loss 2022-02-08At Loss
2022-04-11At Loss 2022-02-07At Loss
2022-04-08At Loss 2022-02-04At Loss
2022-04-07At Loss 2022-02-03At Loss
2022-04-06At Loss 2022-02-02At Loss
2022-04-05At Loss 2022-02-01At Loss
2022-04-04At Loss 2022-01-31At Loss
2022-04-01At Loss 2022-01-28At Loss
2022-03-31At Loss 2022-01-27At Loss
2022-03-30At Loss 2022-01-26At Loss
2022-03-29At Loss 2022-01-25At Loss

PTC Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

PTC Therapeutics Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Traded in other countries / regions
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.